ACOG
Price
$8.90
Change
+$0.61 (+7.36%)
Updated
Nov 9 closing price
Capitalization
180.54M
One day until earnings call
Intraday BUY SELL Signals
KROS
Price
$9.17
Change
-$0.19 (-2.03%)
Updated
Nov 9 closing price
Capitalization
185.58M
113 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACOG vs KROS

ACOG vs KROS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ACOG vs. KROS commentary
Nov 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACOG is a Hold and KROS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ACOG with price predictions
Nov 09, 2026

ACOG in -6.18% downward trend, falling for three consecutive days on November 03, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ACOG declined for three days, in 192 of 226 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for ACOG entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACOG's RSI Oscillator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 69 cases where ACOG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ACOG as a result. In 99 of 120 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for ACOG just turned positive on November 09, 2026. Looking at past instances where ACOG's MACD turned positive, the stock continued to rise in 44 of 57 cases over the following month. The odds of a continued upward trend are 77%.

ACOG moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +9.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACOG advanced for three days, in 158 of 190 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

ACOG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.409) is normal, around the industry mean (3.498). P/E Ratio (-8.726) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.351) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. ACOG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACOG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for KROS with price predictions
Nov 09, 2026

KROS's Stochastic Oscillator stays in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 225 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In 74 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 33 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

KROS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

The Aroon Indicator for KROS entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.498). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. KROS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
KROS: Fundamental Ratings
KROS
OUTLOOK RATING
1..100
65
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
76
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACOGKROS
RSI
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 13 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 1 day ago
75%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Nov 10, 2026
Stock price -- (ACOG: $8.29 vs. KROS: $9.17)
Brand notoriety: ACOG and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACOG: 111% vs. KROS: 82%
Market capitalization -- ACOG: $180.54M vs. KROS: $185.58M
ACOG [@Biotechnology] is valued at $180.54M. KROS’s [@Biotechnology] market capitalization is $185.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACOG’s FA Score shows that 1 FA rating(s) are green while KROS’s FA Score has 1 green FA rating(s).

  • ACOG’s FA Score: 1 green, 4 red.
  • KROS’s FA Score: 1 green, 4 red.
According to our system of comparison, ACOG is a better buy in the long-term than KROS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACOG’s TA Score shows that 4 TA indicator(s) are bullish while KROS’s TA Score has 4 bullish TA indicator(s).

  • ACOG’s TA Score: 4 bullish, 5 bearish.
  • KROS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ACOG is a better buy in the short-term than KROS.

Price Growth

ACOG (@Biotechnology) experienced а -5.15% price change this week, while KROS (@Biotechnology) price change was -14.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.

Reported Earning Dates

ACOG is expected to report earnings on Nov 11, 2026.

KROS is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+2.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ACOG and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACOG has been loosely correlated with KROS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ACOG jumps, then KROS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACOG
1D Price
Change %
ACOG100%
+7.36%
KROS - ACOG
38%
Loosely correlated
-2.03%
ARVN - ACOG
35%
Loosely correlated
+5.46%
ANIX - ACOG
35%
Loosely correlated
-0.47%
MGTX - ACOG
34%
Loosely correlated
+5.44%
SANA - ACOG
33%
Loosely correlated
+4.01%
More

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with SANA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
-2.03%
SANA - KROS
50%
Loosely correlated
+4.01%
IMNM - KROS
46%
Loosely correlated
+3.47%
LXEO - KROS
45%
Loosely correlated
+8.65%
ARVN - KROS
45%
Loosely correlated
+5.46%
EDIT - KROS
45%
Loosely correlated
+7.00%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BEEZ36.710.81
+2.26%
Honeytree U.S. Equity ETF (BEEZ)
GNT8.750.09
+1.04%
GAMCO Natural Resources Gold & Income Trust
HYEM19.210.03
+0.16%
VanEck Emerging Markets High Yield Bond ETF (HYEM)
CSQ20.33N/A
N/A
Calamos Strategic Total Return
DUG15.03-0.17
-1.12%
ProShares UltraShort Energy (DUG)